| Literature DB >> 34155144 |
Meenakshi Chawla1, Tapas Mukherjee1, Alvina Deka1, Budhaditya Chatterjee1,2, Uday Aditya Sarkar1, Amit K Singh3, Saurabh Kedia3, Josephine Lum4, Manprit Kaur Dhillon4, Balaji Banoth1, Subhra K Biswas4, Vineet Ahuja3, Soumen Basak5.
Abstract
Aberrant inflammation, such as that associated with inflammatory bowel disease (IBD), is fueled by the inordinate activity of RelA/NF-κB factors. As such, the canonical NF-κB module mediates controlled nuclear activation of RelA dimers from the latent cytoplasmic complexes. What provokes pathological RelA activity in the colitogenic gut remains unclear. The noncanonical NF-κB pathway typically promotes immune organogenesis involving Nfkb2 gene products. Because NF-κB pathways are intertwined, we asked whether noncanonical signaling aggravated inflammatory RelA activity. Our investigation revealed frequent engagement of the noncanonical pathway in human IBD. In a mouse model of experimental colitis, we established that Nfkb2-mediated regulations escalated the RelA-driven proinflammatory gene response in intestinal epithelial cells, exacerbating the infiltration of inflammatory cells and colon pathologies. Our mechanistic studies clarified that cell-autonomous Nfkb2 signaling supplemented latent NF-κB dimers, leading to a hyperactive canonical RelA response in the inflamed colon. In sum, the regulation of latent NF-κB dimers appears to link noncanonical Nfkb2 signaling to RelA-driven inflammatory pathologies and may provide for therapeutic targets.Entities:
Keywords: NF-κB; Nfkb2; inflammatory bowel disease; intestinal inflammation; noncanonical
Mesh:
Substances:
Year: 2021 PMID: 34155144 PMCID: PMC8237674 DOI: 10.1073/pnas.2024828118
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205